Current management of tuberculosis
Author:
- 1 November 1999
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 1 (1) , 31-41
Abstract
Current chemotherapeutic regimens against tuberculosis give excellent cure rates and low relapse rates if implemented and monitored correctly. This is fortunate since only two new drugs have been approved for use in this condition in the last 30 years. However, shortcomings in management and in patient compliance have resulted in an increasing prevalence of drug-resistant organisms. The global decline in the disease has been reversed due to a combination of factors including the HIV epidemic, ageing populations, poverty, and translocation of refugee populations due to conflict.Keywords
This publication has 39 references indexed in Scilit:
- Issues in the Treatment of Active Tuberculosis in Human Immunodeficiency Virus‐Infected PatientsClinical Infectious Diseases, 1999
- Tuberculosis and PregnancySeminars in Respiratory and Critical Care Medicine, 1998
- RifapentineDrugs, 1998
- Vaccination Against Tuberculosis: Past Problems and Future HopesSeminars in Respiratory and Critical Care Medicine, 1997
- Purification and Characterization of the Mycobacterium smegmatis Catalase-Peroxidase Involved in Isoniazid ActivationJournal of Biological Chemistry, 1995
- Avoidance and Management of Adverse Reactions to Antituberculosis DrugsDrug Safety, 1995
- Clinically Significant Drug Interactions with Antituberculosis AgentsDrug Safety, 1994
- Rapid resolution of tuberculous pericardial effusions with high dose prednisone and anti-tuberculous drugsJournal of Infection, 1994
- In-vitro activities of quinolones against mycobacteriaJournal of Antimicrobial Chemotherapy, 1993
- The management of tuberculous meningitis.Thorax, 1992